354 related articles for article (PubMed ID: 31319641)
21. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.
Yachida S; Vakiani E; White CM; Zhong Y; Saunders T; Morgan R; de Wilde RF; Maitra A; Hicks J; Demarzo AM; Shi C; Sharma R; Laheru D; Edil BH; Wolfgang CL; Schulick RD; Hruban RH; Tang LH; Klimstra DS; Iacobuzio-Donahue CA
Am J Surg Pathol; 2012 Feb; 36(2):173-84. PubMed ID: 22251937
[TBL] [Abstract][Full Text] [Related]
22. Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases.
Carlinfante G; Baccarini P; Berretti D; Cassetti T; Cavina M; Conigliaro R; De Pellegrin A; Di Tommaso L; Fabbri C; Fornelli A; Frasoldati A; Gardini G; Losi L; Maccio L; Manta R; Pagano N; Sassatelli R; Serra S; Camellini L
Virchows Arch; 2014 Jul; 465(1):49-55. PubMed ID: 24807732
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.
Yoxtheimer LM; Heymann JJ; Cohen C; Rao RA; Goyal A; Siddiqui MT
Diagn Cytopathol; 2018 Dec; 46(12):1010-1014. PubMed ID: 30284410
[TBL] [Abstract][Full Text] [Related]
24. Reliability of Ki-67 Determination in FNA Samples for Grading Pancreatic Neuroendocrine Tumors.
Díaz Del Arco C; Díaz Pérez JÁ; Ortega Medina L; Sastre Valera J; Fernández Aceñero MJ
Endocr Pathol; 2016 Dec; 27(4):276-283. PubMed ID: 27688080
[TBL] [Abstract][Full Text] [Related]
25. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
Farrell JM; Pang JC; Kim GE; Tabatabai ZL
Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931
[TBL] [Abstract][Full Text] [Related]
26. Neoplastic Progression in Neuroendocrine Neoplasms of the Pancreas.
Luchini C; Scarpa A
Arch Pathol Lab Med; 2023 Mar; ():. PubMed ID: 36881771
[TBL] [Abstract][Full Text] [Related]
27. Reprint of: The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs).
Heaphy CM; Singhi AD
Hum Pathol; 2023 Feb; 132():1-11. PubMed ID: 36702689
[TBL] [Abstract][Full Text] [Related]
28. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
[TBL] [Abstract][Full Text] [Related]
29. The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors.
Heaphy CM; Singhi AD
Hum Pathol; 2022 Nov; 129():11-20. PubMed ID: 35872157
[TBL] [Abstract][Full Text] [Related]
30. Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication.
Taskin OC; Clarke CN; Erkan M; Tsai S; Evans DB; Adsay V
J Gastrointest Oncol; 2020 Jun; 11(3):548-558. PubMed ID: 32655934
[TBL] [Abstract][Full Text] [Related]
31. Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification.
Xue Y; Reid MD; Pehlivanoglu B; Obeng RC; Jiang H; Memis B; Lui SK; Sarmiento J; Kooby D; Maithel SK; El-Rayes B; Basturk O; Adsay V
Endocr Pathol; 2020 Sep; 31(3):239-253. PubMed ID: 32488621
[TBL] [Abstract][Full Text] [Related]
32. Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.
Roy S; LaFramboise WA; Liu TC; Cao D; Luvison A; Miller C; Lyons MA; O'Sullivan RJ; Zureikat AH; Hogg ME; Tsung A; Lee KK; Bahary N; Brand RE; Chennat JS; Fasanella KE; McGrath K; Nikiforova MN; Papachristou GI; Slivka A; Zeh HJ; Singhi AD
Gastroenterology; 2018 Jun; 154(8):2060-2063.e8. PubMed ID: 29486199
[TBL] [Abstract][Full Text] [Related]
33. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P
Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
[TBL] [Abstract][Full Text] [Related]
34. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution.
Yang M; Zeng L; Ke NW; Tan CL; Tian BL; Liu XB; Xiang B; Zhang Y
BMC Cancer; 2020 Sep; 20(1):906. PubMed ID: 32962649
[TBL] [Abstract][Full Text] [Related]
35. Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors.
Liu TC; Hamilton N; Hawkins W; Gao F; Cao D
Am J Surg Pathol; 2013 Jun; 37(6):853-9. PubMed ID: 23598967
[TBL] [Abstract][Full Text] [Related]
36. Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations.
Navale P; Chatterjee D; Itani M; Trikalinos NA
Virchows Arch; 2023 Aug; 483(2):167-175. PubMed ID: 37354253
[TBL] [Abstract][Full Text] [Related]
37. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
[No Abstract] [Full Text] [Related]
38. Prognostic value of WHO grade in pancreatic neuro-endocrine tumors in Multiple Endocrine Neoplasia type 1: Results from the DutchMEN1 Study Group.
Conemans EB; Brosens LAA; Raicu-Ionita GM; Pieterman CRC; de Herder WW; Dekkers OM; Hermus AR; van der Horst-Schrivers AN; Bisschop PH; Havekes B; Drent ML; Timmers HTM; Offerhaus GJ; Valk GD; Vriens MR
Pancreatology; 2017; 17(5):766-772. PubMed ID: 28811081
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
40. A relook at gastroenteropancreatic neuroendocrine tumours as per 2019 WHO classification-A tertiary centre experience.
Ail DA; Paulose RR
Ir J Med Sci; 2023 Oct; 192(5):2065-2070. PubMed ID: 36409421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]